Page 1,576«..1020..1,5751,5761,5771,578..1,5901,600..»

Top graduating senior in ‘crazy race to the finish line’ | Berkeley News – UC Berkeley

Posted: May 9, 2017 at 4:43 am

In high school, Grant Schroeders tunnel vision earned him the nickname Shrobot, as in robot, as he methodically crammed for an AP calculus test during a rowdy water polo training camp.

That moniker stuck with Schroeder at UC Berkeley, where his unwavering prowess in collegiate athletics, research, public service and a 4.0 GPA has won him the coveted University Medal.

(UC Berkeley video by Melani King).

In the last month alone, he has competed in a national championship triathlon and learned that a paper he co-authored on the cellular mechanics of organ development is a likely contender for publication in the venerable Science magazine.

This Saturday, May 13, Schroeder, 22, an integrative biology major, will address thousands of his peers at a campuswide commencement ceremony as UC Berkeleys top graduating senior. Instead of cataloguing his achievements, his speech will touch on the experiences and vulnerabilities that turned him from methodical to mensch.

At Berkeley, you cant just grind on in a robotic way, Schroeder says. This campus is like a Roman Coliseum where fundamental principles, like free speech and public safety, are constantly clashing. Its really opened my eyes and humanized me.

Dawn, Richard, Erica and Grant Schroeder

A native of 30,000-population Goleta, Santa Barbara County, and the son of a two-time Olympic gold-medalist swimmer, Schroeder admits that, unlike many of his peers, hes been sheltered from many of lifes adversities.

Defying stereotypes

I dont have a huge sob story or defining life story that people can easily sympathize with or empathize with, says Schroeder. I have had struggles here and there, but Im not going to pretend to be someone Im not.

Schroeders mentors are quick to defend him against stereotypes:

We were concerned that his impressive academic record might have given him a sense of arrogance that may not have fit with the often humble and less glamorous grind of day-to-day lab work, wrote Amy Shyer, a researcher in the laboratory of molecular and cell biology professor Richard Harland, in her letter recommending Schroeder for the University Medal.

But once the research team got to know Schroeder, she wrote, It became clear to us that despite his incredible academic success, Grant approaches work and those around him from the perspective of a rigorous hard worker, not from the perspective of a gifted diva.

In August, Schroeder will begin a yearlong research post at Cedars-Sinai Medical Center in Los Angeles where he will experiment with stem cell therapies to regenerate skeletal tissue in animal models. He will also apply to medical school.

As an extreme athlete who has suffered nagging shoulder, back and knee injuries, as well as a bilateral hernia surgery that sidelined him for two months, Schroeder aims to do pioneering work in preventive orthopedics.

Ive put my body through the wringer playing all kinds of sports. Ive seen my teammates sidelined. Ive seen my parents and their friends battle injuries that prevent them from staying active, he says. My goal is to prolong healthy bodies into later life by using strength conditioning and other therapies to prevent injuries before they arise.

Athletics are undeniably in Schroeders genes. His parents, Richard and Dawn, met at UC Santa Barbara as stars on the swim team. Richard Schroeder went on to win gold medals in breaststroke in the 1984 summer Olympics in Los Angeles, and the 1988 summer Olympics in Seoul, Korea.

Athleticism in his genes

I grew up looking up to my dad and his accomplishments and trying to learn from him how to be the best all-round athlete I could be, Schroeder says. He told me, If you want to be the best athlete, or be the best at anything, really, you have to work harder than anyone else and make sacrifices.

All through school, Schroeder played soccer, basketball, baseball and water polo with a tight circle of competitive athletes, many of whom remain his best friends. His younger sister, Erica, is a state track and field champion headed to the University of Washington.

Meanwhile, he inherited his academic drive from his mom, who was his second-grade teacher at Kellogg Elementary in Goleta.

I called her Mrs. Schroeder, not mom. And she was tough on me, he says. She really showed me how to be a good student, respect my teachers, be a good classmate, get good grades and study hard.

After earning top scores in AP calculus, environmental science and world history, among other subjects, Schroeder entered UC Berkeley in fall 2013 as a Regents and Chancellors Scholar. He had also been accepted to UCLA.

UCLA felt more comfortable for me, but I wanted to be a little uncomfortable in college, he says. Berkeleys uniqueness and the fact that its the No.1 public in the nation decided it for me.

He vividly recalls the contrast between the raucous street life on Telegraph Avenue and the view from the top of the Campanile: I took a deep breath, and saw how beautiful the Bay Area was, and soaked it all in.

As an incoming freshman, he joined UC Berkeleys top-ranked water polo team as a walk-on, and had to demonstrate his mettle: I was the smallest player on the team and I had to work hard and prove I could make it, he says.

He made it. Then came the hard knocks. His high school water polo team co-captain, who had gone to UC Santa Barbara, died in a freak drowning accident. Then, the father of another close friend died from cancer.

Breaking out of his cocoon

Id lived a very sheltered, stable life, and it shook me up, he says. Experiencing loss has also been really crucial to my development.

Another setback was the breakup of his first romantic relationship, which he began in his sophomore year: It actually really hurts, he says. And thats an intense emotion that I had never felt before.

In his junior year, Schroeder quit water polo to focus on research and expand his horizons. He got an internship with the P3 Peak Performance Project, an organization that trains high-level athletes.

Through the campuss Undergraduate Research Apprentice Program, he landed a research position with the Harland Lab, where he worked closely with two postdoctoral researchers on how cells and tissue evolve into functioning organs. Specifically, they tracked follicle patterns in chicken skin to better understand the underlying mechanics of organ development.

His contributions earned him the distinction of second author on a paper under review in Science magazine, an honor usually reserved for senior researchers. Moreover, his key experiments also opened up a new topic area of exploration for us, which we used as the basis for a $1 million National Institutes of Health grant, Shyer wrote in her recommendation letter.

An unexpected growth experience for him were the mental-health check-ins that his research team conducted whenever they met.

At first I thought, Why should it matter how Im feeling? Im just here to do work, he says. But then it became refreshing to say, I feel good today, or Im stressed out about an exam. It opened me up.

As a volunteer, Schroeder mentored new undergraduates in the Harland Lab, and high school students in Oaklands College Prep STEM research program.

And, as captain of the Cal Triathlon Team, he brought the NCAA Womens West Region National Qualifier to UC Berkeley, allowing Cals top female triathletes, he says, to compete in their own backyard.

One triathlon hell never forget is last months national collegiate championship in Tuscaloosa, Alabama. There he was, charging ahead of the pack, the finish line in sight, when his legs suddenly buckled and he crashed into the barricades.

People were passing me, and I couldnt stand. I couldnt use my legs, he says. Then out of the blue, two racers I didnt know scooped me up and carried me to the finish line in an amazing display of sportsmanship.

And that about sums up Schroeders life so far: Its been a crazy race to the finish line, he says. Im looking forward to what comes next.

Read the rest here:
Top graduating senior in 'crazy race to the finish line' | Berkeley News - UC Berkeley

Posted in Alabama Stem Cells | Comments Off on Top graduating senior in ‘crazy race to the finish line’ | Berkeley News – UC Berkeley

ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain – Barron’s

Posted: May 9, 2017 at 4:43 am


Barron's
ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain
Barron's
Meanwhile the SPDR S&P Biotech ETF (XBI), the SPDR S&P Pharmaceuticals ETF (XPH), and the First Trust NYSE Arca Biotechnology Index (FBT) fell about 2.7% apiece. The AHCA could have both positive and negative impact on pharma and biotech, but ...

and more »

View original post here:
ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain - Barron's

Posted in Biotechnology | Comments Off on ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain – Barron’s

Puma Biotechnology Stock Slumps as Regulatory VP Departs Before FDA Review – Los Angeles Business Journal

Posted: May 9, 2017 at 4:43 am

Puma Biotechnology Inc.s stock took a dive last week after its regulatory executive resigned less than three weeks before a U.S. Food and Drug Administration panel is scheduled to review the public companys breast cancer drug Neratinib.

The Westwood companys share price dipped 14 percent to $31.38 at the close of business May 5 from $36.45 the day before, when the company notified the Securities and Exchange Commission that Robert Charnas, senior vice president of regulatory affairs and project management, would step down for health reasons effective May 15.

The stock was trading at $29.15 when the markets closed Monday.

The company, which has a market cap of $1.07 billion, hired 63-year-old Charnas last year with a base salary of more than $330,000, stock options, and a more than $378,000 signing bonus, according to the employment offer letter filed with the SEC.

An independent panel of experts is scheduled to review Neratinib for safety and efficacy May 24 before making a recommendation for its use to the FDA.

Caroline Anderson is a staff reporter covering retail, restaurants, and hospitality. She can be reached at canderson@labusinessjournal.com.

View post:
Puma Biotechnology Stock Slumps as Regulatory VP Departs Before FDA Review - Los Angeles Business Journal

Posted in Biotechnology | Comments Off on Puma Biotechnology Stock Slumps as Regulatory VP Departs Before FDA Review – Los Angeles Business Journal

Animal Biotechnology Technologies, Markets and Companies 2016 … – PR Newswire (press release)

Posted: May 9, 2017 at 4:43 am

This report describes and evaluates animal biotechnology and its application in veterinary medicine and pharmaceuticals as well as improvement in food production. Knowledge of animal genetics is important in the application of biotechnology to manage genetic disorders and improve animal breeding. Genomics, proteomics and bioinformatics are also being applied to animal biotechnology.

Transgenic technologies are used for improving milk production and the meat in farm animals as well as for creating models of human diseases. Transgenic animals are used for the production of proteins for human medical use. Biotechnology is applied to facilitate xenotransplantation from animals to humans. Genetic engineering is done in farm animals and nuclear transfer technology has become an important and preferred method for cloning animals.There is discussion of in vitro meat production by culture.

Biotechnology has potential applications in the management of several animal diseases such as foot-and-mouth disease, classical swine fever, avian flu and bovine spongiform encephalopathy. The most important biotechnology-based products consist of vaccines, particularly genetically engineered or DNA vaccines. Gene therapy for diseases of pet animals is a fast developing area because many of the technologies used in clinical trials humans were developed in animals and many of the diseases of cats and dogs are similar to those in humans.RNA interference technology is now being applied for research in veterinary medicine.

Molecular diagnosis is assuming an important place in veterinary practice. Polymerase chain reaction and its modifications are considered to be important. Fluorescent in situ hybridization and enzyme-linked immunosorbent assays are also widely used. Newer biochip-based technologies and biosensors are also finding their way in veterinary diagnostics.

Approximately 124 companies have been identified to be involved in animal biotechnology and are profiled in the report. These are a mix of animal healthcare companies and biotechnology companies. Top companies in this area are identified and ranked. Information is given about the research activities of 11 veterinary and livestock research institutes. Important 108 collaborations in this area are shown.

Share of biotechnology-based products and services in 2016 is analyzed and the market is projected to 2026.

The text is supplemented with 35 tables and 5 figures.Selected 260 references from the literature are appended.

Key Topics Covered:

Executive Summary

1. Introduction to Animal Biotechnology

2. Application of Biotechnology in Animals

3. A Biotechnology Perspective of Animals Diseases

4. Molecular Diagnostics in Animals

5. Biotechnology-based Veterinary Medicine

6. Research in Animal Biotechnology

7. Animal Biotechnology Markets

8. Regulatory issues

9. Companies Involved in Animal Biotechnology

10. References

For more information about this report visit http://www.researchandmarkets.com/research/mdr33b/animal

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/animal-biotechnology-technologies-markets-and-companies-2016-2026-with-profiles-of-the-top-companies---research-and-markets-300452977.html

SOURCE Research and Markets

http://www.researchandmarkets.com

Originally posted here:
Animal Biotechnology Technologies, Markets and Companies 2016 ... - PR Newswire (press release)

Posted in Biotechnology | Comments Off on Animal Biotechnology Technologies, Markets and Companies 2016 … – PR Newswire (press release)

Puma Biotechnology Inc (PBYI) Plunges 5.54% on May 08 – Equities.com

Posted: May 9, 2017 at 4:43 am

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Puma Biotechnology Inc (PBYI) had a rough trading day for Monday May 08 as shares tumbled 5.54%, or a loss of $-1.7 per share, to close at $29.00. After opening the day at $30.45, shares of Puma Biotechnology Inc traded as high as $31.20 and as low as $28.50. Volume was 1.11 million shares over 8,212 trades, against an average daily volume of 941,762 shares and a total float of 36.97 million.

As a result of the decline, Puma Biotechnology Inc now has a market cap of $1.07 billion. In the last year, shares of Puma Biotechnology Inc have traded between a range of $73.27 and $19.74, and its 50-day SMA is currently $38.11 and 200-day SMA is $43.37.

For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 160 employees. Its CEO is Alan H. Auerbach.

Puma Biotechnology Inc is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

More here:
Puma Biotechnology Inc (PBYI) Plunges 5.54% on May 08 - Equities.com

Posted in Biotechnology | Comments Off on Puma Biotechnology Inc (PBYI) Plunges 5.54% on May 08 – Equities.com

Biotechnology sachet solution launched – Cleaning & Maintenance

Posted: May 9, 2017 at 4:43 am

London-based Cleanology is launching what it claims to be the worlds first biotech wipe for tablets and mobile phones, and pre-portioned cleaning fluids and floor cleaners in sachets.

Biotechnology uses enzymes to eat dirt and bacteria. The tiny molecules access even the hardest to reach areas and carry on working for days after application. Enzyme-based solutions are gaining traction in the industry, but to date no firm has focused on mobile device screens, which are often taken out of the office at night, when cleaning takes place.

Cleanology has created a multi-purpose biotech tech wipe which cleans and sanitises mobile phones, tablets and laptops with a moist tissue impregnated with a biotechnology cleaning solution. It has also addressed portioning, with the development of handy-sized sachets which hold a pre-dosed amount of solution. When added to water, this creates a biotechnology cleaning agent.

CEO Dominic Ponniah said: Biotechnology is a fantastic advance which has rightly been embraced by the industry. However, as with all cleaning products that require dilution, people often use too much product - they think that the more they slosh into a bucket, the more effective they will be. Using too much product - especially biotechnology products which are pH-neutral and completely safe - does not cause any harm, but it is wasting valuable resources. An extra cupful of solution every couple of days might not seem disastrous, but multiply that over a year and across the 450,000 people working in the industry, and the impact becomes significant. The cleaning firm ends up buying larger quantities of product and paying more to transport it, not to mention the environmental impact of extra journeys, waste generation and the unnecessary manufacture of products.

To counteract this excess, Cleanology has introduced its own range of pre-portioned biotechnology solutions and wipes. Each sachet of multi-purpose or floor cleaner is sufficient to fill one bucket or spray can, with a pack of 50 sachets able to last a month. The sachets fit easily into the pocket, so a cleaning operative can carry supplies with them from job to job. The wipes are impregnated with biotechnology solution and pre-diluted with water.

Cleanology was one of the first cleaning firms to embrace biotechnology. It has partnered with InnuScience, a leader in the development and manufacture of biotechnology cleaning products. Ponniah continued: InnuScience are experts in their field, supplying all the major FM companies and retail brands. We are experts in cleaning, while InnuScience provides the cutting-edge technology thats inside our Bioclean sachets.

Link:
Biotechnology sachet solution launched - Cleaning & Maintenance

Posted in Biotechnology | Comments Off on Biotechnology sachet solution launched – Cleaning & Maintenance

First public sector stem cell bank to come up at KGMU – Times of India

Posted: May 9, 2017 at 4:42 am

LUCKNOW: In what may come as a relief to over 1 lakh patients of thalassemia in India, a public sector stem cell bank is set to come up at UP's King George's Medical University here. A project of the university's transfusion medicine department, the stem cell bank would roll out stem cell therapy to patients of thalassemia and sickle cell anaemia. The proposal is awaiting clearance from state department of medical education.

Stem cells are omnipotent and can take shape of any cell inside the body. If infused in the pancreas, stem cells will become pancreatic while in the liver, they will become liver cells.

These are found in human bone marrow and can be derived from the umbilical cord which contains blood vessels that connect baby in the womb to the mother to ingest nutrition required for development.

Research on the therapeutic use of stem cells is underway in US, Europe, China, South East Asia besides India. In UP, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS) and KGMU are both trying to explore the potential of stem cells to treat various health problems. SGPGI has, so far, restricted itself to use of allogenic (stem cells derived from bone marrow of a person), while KGMU has used stem cells derived from the umbilical cord.

Head of transfusion medicine department of KGMU, Prof Tulika Chandra said, "Several private sector stem cell banks like Life Cell and Cord Life India are operating in India but they serve only those who have deposited the baby's cord, while our bank will help everyone."

KGMU has sustained access to umbilical cord because of a very developed obstetrics and gynaecology department. The cord is gathered from the placenta in the uterus of pregnant women which nourishes and maintains the baby through the umbilical cord.

Sources in medical education department said the proposal is worth Rs 9 crore including infrastructure cost. "Stem cell bank promises to become financially self-sustaining within 2-3 years of inception," said a directorate officer.

Talking about why children with thalassemia and sickle cell anaemia were chosen, Chandra said, "Global literature shows umbilical cord stem cells can induce extraordinary results on such children. In fact, success rate is around 70-75% and higher score can be achieved if therapy is provided at an earlier age."

Follow this link:
First public sector stem cell bank to come up at KGMU - Times of India

Posted in Cell Medicine | Comments Off on First public sector stem cell bank to come up at KGMU – Times of India

Two Day FDA’s Regulation of Regenerative Medicine Seminar … – Business Wire (press release)

Posted: May 9, 2017 at 4:42 am

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "FDA's Regulation of Regenerative Medicine including Stem Cell Treatments, Tissue Engineering & Gene Therapies: 2-Day In-person Seminar" conference to their offering.

Stem cells harness the power to differentiate into numerous cells upon stimulation. This has led to their wide exploration across all of medicine, including high risk diseases. Of course, significant scientific breakthroughs in the use of stem cells to prevent, diagnose, and treat numerous diseases has caused numerous start-up companies to form. Despite, such promise, the FDA has yet to approve stem cell therapies for a wide range of diseases, except cord blood-derived hematopoietic progenitor cells for certain indications.

This tutorial will provide an historical context for the use of stem cells in medicine, where the field has been and where it is going. It will also provide the few examples of FDA approved use of stem cells in medicine and what is needed for the field to progress. For example, in 2006, the U.S. FDA implemented regulations governing the use of human cells, tissues, and cellular and tissue-based products in humans including bone, ligament, skin, dura mater, stem cells, cartilage cells, and various other cellular and tissue-based products. Currently, there is an ongoing debate in industry on how such therapies should be regulated, in particular by the FDA or under the practice of medicine, under federal law or state law, and as drugs or simply biologics.

Learning Objectives:

Fundamentals of stem cells

- What is all the excitement about

- How to control stem cell differentiation

- Sources of stem cells

- Incorporating stem cells into biomaterials

- Avoiding immune system clearance of stem cells

FDA regulatory approvals for the use of stem cells in medicine

- Currently approved use of stem cells in medicine

- FDA guidance documents for stem cell technologies

- Global approval of stem cell technologies

- How the FDA regulates regenerative treatments and therapies

- The use of human cells, tissues, and cellular and tissue-based product criteria and Minimal Manipulation Standard

- The drug and biological approval process

- Regenerative products as medical devices

- How to design appropriate clinical trials

- Applicable good manufacturing and good laboratory practices

- Product labeling, marketing and advertising

- FDA and other federal agency enforcement action

Future thoughts on approaches for regulatory approval of stem cell technologies

- Remaining hurdles

- Outlook for new technologies

For more information about this conference visit http://www.researchandmarkets.com/research/ljt255/fdas_regulation

See the original post:
Two Day FDA's Regulation of Regenerative Medicine Seminar ... - Business Wire (press release)

Posted in Cell Medicine | Comments Off on Two Day FDA’s Regulation of Regenerative Medicine Seminar … – Business Wire (press release)

Reprogrammed Cells Improve Heart Function After a Heart Attack – Medical News Bulletin

Posted: May 9, 2017 at 4:42 am

In a recent study published in Circulation, researchers managed to convert de-differentiated human fibroblasts, support cells key in healing, to red blood cells or cells that line the interiors of blood vessels via manipulation of the SOX17 transcription factor. The de-differentiated fibroblasts can improve heart function after a heart attack and provide patient-specific cells that do not suffer from premature aging.

Fibroblasts, a support cell key in healing, are commonly used for de-differentiation. De-differentiated cells are similar to stem cells; depending on the environment they are in and what genes are active, they become different cells. De-differentiated cells have many medical uses; as many as the number of cells that they can become. In a recent study published in Circulation, researchers from the University of Illinois College of Medicine and the Indiana University School of Medicine managed to convert de-differentiated human fibroblasts to endothelial cells and erythroblasts. Endothelial cells are the cells that make up the lining of the interior of blood vessels. Erythroblasts are commonly known as red blood cells.

The researchers first de-differentiated the fibroblasts by overexpression of the proteins that transcribe DNA into RNA, specifically, pluripotency transcription factors. The de-differentiated cells were then placed into different media to transform them into endothelial cells and erythroblasts. The researchers observed that a specific transcriptional regulator, SOX17, and its respective activity corresponded to which cell the de-differentiated fibroblasts became. The researchers also experimented on rats that had suffered heart attacks. They implanted the de-differentiated fibroblasts into the rats and found that they improved heart function after a heart attack. Finally, the researchers observed that the cells generated from the de-differentiated fibroblast had increased production of telomerase. Telomerase is a transcription factor that produces telomeres, which are at the ends of chromosomes. The length of telomeres corresponds to the age of a cell, with longer being younger.

All this research shows the power of de-differentiated cells. De-differentiated fibroblasts can make patient-specific cells. These cells may avoid premature aging because of the increased production of telomerase: Helpful for enabling older patients to have personalized cells. Though only shown in mice, the de-differentiated fibroblasts did improve cardiac function after their heart attacks and may benefit humans as well. Pinpointing SOX17 as the switch for making endothelial cells or erythroblasts will optimize their generation, which will prove valuable for tissue regeneration and disease modeling.

Written By:Brian Jones

See original here:
Reprogrammed Cells Improve Heart Function After a Heart Attack - Medical News Bulletin

Posted in Cell Medicine | Comments Off on Reprogrammed Cells Improve Heart Function After a Heart Attack – Medical News Bulletin

Aspirin, other antiplatelet drugs boost T-cell therapy in mice with … – FierceBiotech

Posted: May 9, 2017 at 4:41 am

Engineered T-cell therapies, a promising way to prime a patients immune system against cancer, dont work for everyone. Scientists from the Medical University of South Carolina (MUSC)found one possible explanation that can be targeted: blood platelets.

The immune system sees tumors, or uncontrolled cell growth, as part of the self, which allows cancer to evade immune attack. In adoptive T-cell therapy, a patients own T cells are isolated from his or her blood, and then primed to recognize tumor cells.

Previous research has shown that some cancers curb T-cell activity and that platelets, a component of blood responsible for clotting, might make cancer worse. The MUSC team, led by senior author Zihai Li, M.D., Ph.D.,found that platelets help cancer to hide by secreting a molecule, TGF-beta, that suppresses T cells.

RELATED: New culture method boosts T cells' ability to recognize multiple cancers

While most TGF-beta is inactive, the researchers found that GARP, a molecular hook on the surface of platelets, traps and activates TGF-beta. As a result, platelets become the main source of TGF-beta used by tumor cells to tamp down on T-cell function, according to a statement.

The team ran a battery of preclinical trials, finding that a T-cell therapy more effectively awoke the immune system when given alongside common antiplatelet drugs, such as aspirin.

First, they noticed that melanoma tumors grew more slowly in mice with defective platelets than in mice with normal platelets. Adoptive T-cell therapy was more effective in genetically modified mice without GARP. And mice with normal platelets and melanoma that were given T-cell therapy along with aspirin and clopidogrelsurvived longer and relapsed less, according to the statement. But antiplatelet drugs alone did not fight the cancer.

"We can test simple, over-the-counter antiplatelet agents to really improve immunity and make a difference in how to treat people with cancer, Li said. The study was published in Nature Immunology.

This study could lay the foundation for further work testing antiplatelet approaches in melanoma and other cancers. Melanoma is not currently treated with adoptive T-cell therapy, but with checkpoint inhibitors, such as Bristol-Myers Opdivo and Yervoy.

Go here to read the rest:
Aspirin, other antiplatelet drugs boost T-cell therapy in mice with ... - FierceBiotech

Posted in Cell Therapy | Comments Off on Aspirin, other antiplatelet drugs boost T-cell therapy in mice with … – FierceBiotech

Page 1,576«..1020..1,5751,5761,5771,578..1,5901,600..»